Quick summary - Seer, the Redwood City, California-based proteomics company, reported a set of commercial and financial updates in an investor presentation filed with the U.S. Securities and Exchange Commission. The filing, timed ahead of Seer’s Annual Meeting of Stockholders scheduled for July 28, 2026, triggered a 30% rise in the company’s share price on Monday.
The presentation, which applies to stockholders of record as of May 29, 2026 who will be eligible to vote at the meeting, summarized Seer’s view of the commercial opportunity and recent operational performance. In it, the company reiterated its projection that the proteomics market could become a $23 billion total addressable market by 2034, and it highlighted customer traction in its installed base.
Seer reported that its installed base has expanded at a 62% compound annual growth rate since 2021. The company attributed that expansion in part to partnerships with major mass spectrometry platforms that support its commercial footprint.
Financial and operational discipline were also focal points of the presentation. Seer said it has cut annual cash burn by 36% since 2022 and has achieved meaningful year-over-year reductions in selling, general and administrative expenses and research and development spending each year since 2023. The company noted that cumulative peer-reviewed publications referencing its work doubled over the last year, totaling 84 since 2022.
On the balance sheet, Seer reported approximately $220 million in cash and stated it carries no debt. The board has approved up to $50 million in share repurchases under a buyback program, with $25.5 million still available under that authorization.
Stock-based compensation has been reduced substantially, with the company reporting an approximate 75% decline since 2023. Seer said stock-based compensation had been reduced to an annualized run rate of $8.5 million in 2026.
The timing of the presentation coincides with an ongoing proxy contest. Seer’s board urged stockholders to support its slate of seven director nominees by voting on the company’s blue proxy card. The board also stated that it has rejected proposals put forward by Bradley Radoff and Michael Torok, who are attempting to replace members of the board.
Investors will consider the presentation and governance developments ahead of the July 28 meeting. The company’s statements and the outstanding proxy challenge were both presented in the SEC filing made public in advance of the vote.